4 results about "Hiv gp120" patented technology

The present application relates to a compositions and methods comprising or expressing a hevamine A-related MoMo30 protein from Momordica balsamina. The MoMo30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients, and comprises an amino acid sequence of SEQ ID NO: 4. The MoMo30 protein and / or a nucleic acid encoding the same may be used in methods for preventing or treating microbial infections by HIV, SARS-CoV-2 and other enveloped viruses, as well as other microorganisms comprising cell surface proteins containing glycan residues, such as mannose.

The invention discloses a multispecific anti-gp120 artificial antibody as well as a preparation method and application thereof. The multispecific anti-gp120 artificial antibody is prepared from gold nanoparticles and polypeptide, the two ends of the polypeptide are fixedly connected to the surfaces of the gold nanoparticles through Au-S bonds. According to the invention, the SPR (Surface Plasmon Resonance) technology is utilized to prove that the multispecific anti-gp120 artificial antibody has strong binding force and high affinity to gp120. The cost of the novel multispecific anti-gp120 artificial antibody is the same as that of a single monospecific gold antibody, but the affinity of the novel multispecific anti-gp120 artificial antibody with gp120 is higher, and the novel multispecific anti-gp120 artificial antibody is expected to effectively neutralize various gp120 mutants and inhibit immune escape of HIV viruses. Gp120 of HIV can be prevented from being combined with host cells CD4, and the application prospect in the aspect of HIV prevention and treatment is achieved.

The application provides a polypeptide molecule for specifically recognizing HIV gp120 protein and an application thereof, and belongs to the technical field of biological medicine. The application provides a lead polypeptide derivative for specifically targeting and combining HIV gp120, wherein the lead polypeptide comprises an amino acid sequence shown in SEQ ID No. 1. The application also provides a lead polypeptide derivative prepared based on the lead polypeptide, and a polypeptide nanoparticle constructed by the lead polypeptide derivative, and both of them have gp120 protein combining capacity. The derivative and the nanoparticle have good virus neutralization inhibition effect. The series of polypeptide molecules can specifically combine with free HIV virus, HIV infected cells and free gp120, so as to block HIV infected cells, delay the AIDS disease process, realize AIDS treatment drug targeted delivery, detection and diagnosis.

Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 CD4 binding site (CD4bs) region.